TABLE 1.
Antimicrobial activity of tedizolid tested against resistant phenotypes of E. faecalis and E. faecium causing invasive infections in hospitalized patients in U.S. and European medical centers, 2015 to 2017
| Organism and phenotypea | No. tested | No. (cumulative %) of isolates inhibited at MIC (mg/liter) of: |
MIC (mg/liter) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | >1 | MIC50 | MIC90 | ||
| E. faecalis | 1,342 | 1 (0.1) | 16 (1.3) | 394 (30.6) | 813 (91.2) | 117 (99.9) | 0 (99.9) | 1 (100) | 0.25 | 0.25 |
| HLAR | 402 | 1 (0.2) | 5 (1.5) | 147 (38.1) | 235 (96.5) | 13 (99.8) | 0 (99.8) | 1 (100) | 0.25 | 0.25 |
| VRE | 28 | 1 (3.6) | 0 (3.6) | 11 (42.9) | 13 (89.3) | 3 (100) | 0.25 | 0.5 | ||
| VRE-HLAR | 21 | 1 (4.8) | 0 (4.8) | 8 (42.9) | 11 (95.2) | 1 (100) | 0.25 | 0.25 | ||
| Daptomycinb | 44 | 0 (0) | 11 (25) | 31 (95.5) | 2 (100) | 0.25 | 0.25 | |||
| E. faecium | 916 | 3 (0.3) | 29 (3.5) | 340 (40.6) | 442 (88.9) | 97 (99.5) | 5 (100) | 0.25 | 0.25 | |
| HLAR | 231 | 7 (3) | 89 (41.6) | 110 (89.2) | 23 (99.1) | 2 (100) | 0.25 | 0.5 | ||
| VRE | 343 | 2 (0.6) | 16 (5.2) | 140 (46.1) | 158 (92.1) | 26 (99.7) | 1 (100) | 0.25 | 0.25 | |
| HLAR-VRE | 75 | 1 (1.3) | 34 (46.7) | 32 (89.3) | 8 (100) | 0.25 | 0.5 | |||
| Daptomycinb | 369 | 1 (0.3) | 6 (1.9) | 109 (31.4) | 208 (87.8) | 41 (98.9) | 4 (100) | 0.25 | 0.5 | |
| VRE and daptomycinb | 115 | 2 (1.7) | 44 (40) | 58 (90.4) | 10 (99.1) | 1 (100) | 0.25 | 0.25 | ||
| HLAR-VRE and daptomycinb | 30 | 13 (43.3) | 14 (90.0) | 4 (100) | 0.25 | 0.25 | ||||
a
HLAR, high-level aminoglycoside resistance; VRE, vancomycin-resistant enterococci.
b
Daptomycin MIC, ≥2 mg/liter.